Subscribe
gil-c-shutterstock-com-4-1-merck
Gil C / Shutterstock.com
3 May 2016Americas

Gilead v Merck hepatitis C dispute rocked by new allegation

A judge assessing a patent dispute between Merck and Gilead centring on hepatitis C treatments has allowed Gilead to submit new evidence of jurors allegedly being misled.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Merck to pay Gilead $14m in attorneys’ fees
20 July 2017   A California district court has awarded Gilead Sciences $13.8 million in attorneys’ fees in a patent dispute against Merck & Co, Merck Sharp & Dohme and Isis Pharmaceuticals.
Americas
Judge overturns $200m award in Gilead v Merck
9 June 2016   A US court has overturned an earlier ruling in which Merck was awarded $200 million in damages for patent infringement after finding that the pharmaceutical company had engaged in misconduct.
Americas
Merck handed $200m in Gilead hepatitis C row
29 March 2016   Gilead has been ordered to pay Merck $200 million in damages following a trial that found it had infringed patents covering hepatitis C treatments.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Americas
Merck to pay Gilead $14m in attorneys’ fees
20 July 2017   A California district court has awarded Gilead Sciences $13.8 million in attorneys’ fees in a patent dispute against Merck & Co, Merck Sharp & Dohme and Isis Pharmaceuticals.
Americas
Judge overturns $200m award in Gilead v Merck
9 June 2016   A US court has overturned an earlier ruling in which Merck was awarded $200 million in damages for patent infringement after finding that the pharmaceutical company had engaged in misconduct.
Americas
Merck handed $200m in Gilead hepatitis C row
29 March 2016   Gilead has been ordered to pay Merck $200 million in damages following a trial that found it had infringed patents covering hepatitis C treatments.

More on this story

Americas
Merck to pay Gilead $14m in attorneys’ fees
20 July 2017   A California district court has awarded Gilead Sciences $13.8 million in attorneys’ fees in a patent dispute against Merck & Co, Merck Sharp & Dohme and Isis Pharmaceuticals.
Americas
Judge overturns $200m award in Gilead v Merck
9 June 2016   A US court has overturned an earlier ruling in which Merck was awarded $200 million in damages for patent infringement after finding that the pharmaceutical company had engaged in misconduct.
Americas
Merck handed $200m in Gilead hepatitis C row
29 March 2016   Gilead has been ordered to pay Merck $200 million in damages following a trial that found it had infringed patents covering hepatitis C treatments.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims